Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R1PZ
|
|||
| Former ID |
DIB013949
|
|||
| Drug Name |
F-15063
|
|||
| Synonyms |
D2/D3 antagonists (psychosis/schizophrenia), Pierre Fabre
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Preclinical | [1] | |
| Company |
Centre de Recherche Pierre Fabre
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H29NO2
|
|||
| Canonical SMILES |
CC1(CC2=C(O1)C(=CC=C2)OCCNCC3=CC(=CC=C3)C4=CCCC4)C
|
|||
| InChI |
1S/C24H29NO2/c1-24(2)16-21-11-6-12-22(23(21)27-24)26-14-13-25-17-18-7-5-10-20(15-18)19-8-3-4-9-19/h5-8,10-12,15,25H,3-4,9,13-14,16-17H2,1-2H3
|
|||
| InChIKey |
RAIDOKRWKAIHOH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 680203-70-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D2 receptor (D2R) | Target Info | Modulator | [2] |
| Dopamine D3 receptor (D3R) | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Rap1 signaling pathway | ||||
| cAMP signaling pathway | ||||
| Gap junction | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| Hypothetical Network for Drug Addiction | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026348) | |||
| REF 2 | F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.Naunyn Schmiedebergs Arch Pharmacol.2007 Jun;375(4):241-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.